Among patients with obstructive sleep apnea and excessive daytime sleepiness-related cognitive impairment, 2-week solriamfetol led to cognitive function improvement on three tests/scales, according to ...

Among patients with obstructive sleep apnea using CPAP, pitolisant given at 20 mg and 40 mg reduces excessive daytime sleepiness.

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

People with certain types of long-term sleep disorders feel extremely tired during the day, a condition known as excessive daytime sleepiness (EDS). There are many medicines that work in different ...

Given sleep’s profound impact on well-being, unexplained daytime fatigue and disrupted sleep patterns necessitate a ...

Axsome Therapeutics said it's dopamine and norepinephrine reuptake inhibitor solriamfetol (Sunosi), approved for excessive ...

Q: Should I be worried about Obstructive Sleep Apnea? Obstructive Sleep Apnea is estimated to affect 25 million Americans or ...

Axsome Therapeutics (AXSM) announced results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder, MDD, ...

UC San Francisco study finds women over 80 who experience increased daytime sleepiness face twice the risk of developing ...

If you have a long-term sleep disorder that causes excessive daytime sleepiness (EDS), you may need to take medicines to manage your symptoms. The different medicines available for these ...